About Us

We're Redefining Cancer Treatment

At Kazia, we believe the future of oncology lies in overcoming the biological mechanisms that drive immunotherapy resistance, metastasis, cancer recurrence, and treatment failure. We are focused on some of the most challenging solid tumors, including brain and breast cancers, where immunotherapy has historically delivered limited benefit. By combining translational science with clinical development expertise, we are advancing next-generation therapies designed to transform outcomes for patients and redefine what is possible in cancer treatment.

Our Mission

Our mission is to pioneer best-in-class therapeutics that reprogram the tumor microenvironment to overcome immune resistance and enable effective, durable anti-tumor responses. We are committed to developing highly selective therapies that target disease-driving phenotypes while sparing healthy tissues, delivering more precise and effective treatment options for patients with difficult-to-treat cancers.

An Advancing Strategy

Our strategy is centered on harnessing deep expertise in translational tumor biology and leveraging state-of-the-art multi-modal technology platforms to identify and develop breakthrough oncology therapies. By targeting the fundamental biological pathways that drive tumor progression, immune escape, metastasis, and recurrence, we are building a portfolio of differentiated programs with the potential to address significant unmet needs across solid tumors.

An Actionable Approach

Our approach combines rigorous translational research with disciplined clinical development to accelerate the delivery of innovative therapies to patients. We focus on therapeutic mechanisms with strong scientific rationale and measurable biological impact, using cutting-edge technologies to develop next-generation, best-in-class medicines that selectively target cancer while rewiring the tumor–immune ecosystem to unlock the full potential of immunotherapy.

We’re Strategically Positioned for Market Expansion

Our pipeline is strategically aligned with high-growth therapeutic areas, where innovation in oncology is driving market expansion, and emerging modalities are broadening treatment options for cancers that have historically been resistant to therapy.

Best- & First-in-Class Development Pipeline

Kazia Therapeutics is a clinical-stage oncology company focused on developing therapies for aggressive solid tumors. We are advancing a new paradigm in cancer treatment by leveraging precision pathway inhibition to reprogram cancer biology, restore anti-tumor immunity, and overcome treatment resistance.

View Our Pipeline

Precision Technology

That Transforms Therapies

Our expertise in precision humanized technologies, together with a multi-modal understanding of transcription and epigenetics enhances the evolving direction of oncology drug development.

View Our Technology

We’re Accelerating with Impactful Partnerships

We collaborate with leading research institutions and industry partners worldwide to accelerate the discovery and development of pioneering cancer therapeutics. Our partnerships include: 

  • Genentech
  • Simcere Zaiming
  • QIMR Berghofer
  • Evotec SE
  • Sovargen
  • Pacific Pediatric Neuro-Oncology Consortium
  • Memorial Sloan Kettering Cancer Center
  • Johns Hopkins Medicine
  • Dana-Farber Cancer Institute
  • The Royal Brisbane and Women’s Hospital
  • The Canberra Hospital

Our Expert Leadership is Shaping the Future

Our team brings deep expertise across drug development and discovery, epigenetics, corporate strategy, operations, finance, capital markets, and business development. Together, we are driven by scientific excellence, strategic vision, and a shared commitment to transform outcomes for patients facing the most challenging cancers.

View Management Team View Board of Directors